scholarly journals New metformin derivative HL156A prevents oral cancer progression by inhibiting the insulin-like growth factor/AKT/mammalian target of rapamycin pathways

2018 ◽  
Vol 109 (3) ◽  
pp. 699-709 ◽  
Author(s):  
Thuy Giang Lam ◽  
Yun Soo Jeong ◽  
Soo-A Kim ◽  
Sang-Gun Ahn
Keyword(s):  
Growth Factor ◽  
Oral Cancer ◽  
Cancer Progression ◽  
Mammalian Target Of Rapamycin ◽  
Target Of Rapamycin ◽  
Insulin Like Growth Factor

Insulin-Like Growth Factor 1/Mammalian Target of Rapamycin and AMP-Activated Protein Kinase Signaling Involved in the Effects of Metformin in the Human Endometrial Cancer

2016 ◽  
Vol 26 (9) ◽  
pp. 1667-1672 ◽  
Author(s):  
Dongge Cai ◽  
Hongli Sun ◽  
Yanhua Qi ◽  
Xiaogui Zhao ◽  
Minjuan Feng ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Growth Factor ◽  
Protein Kinase ◽  
Molecular Mechanisms ◽  
Pilot Trial ◽  
Plasma Concentrations ◽  
Mammalian Target Of Rapamycin ◽  
Target Of Rapamycin ◽  
Insulin Like Growth Factor ◽  
Amp Activated Protein Kinase

BackgroundMetformin is a well-tolerated biguanide drug used for decades to treat type 2 diabetes mellitus. In recent years, long-term administration of metformin has been found to reduce carcinogenic risk for cancers derived from various tissues. However, its cellular and molecular mechanisms of anticancer action in the endometrial cancer (EC) have not yet been fully elucidated.Patients and MethodsSixty patients diagnosed as endometrial carcinoma were grouped into (n = 30) and non-treatment mixed (n = 30) for analysis. Thirty healthy donors are control groups. We attempt to investigate the interaction of metformin, insulin-like growth factor 1 (IGF-1) expression, and phosphorylated mammalian target of rapamycin (p-mTOR) and AMP-activated protein kinase (p-AMPK).ResultsWe found that high IGF-1 plasma concentrations in women with EC were reversed by conventional antidiabetic doses of metformin in the present work. In parallel, the activation of AMPK and suppression of mTOR seemed to play an important role for the effect of metformin in patients with EC.ConclusionsThis pilot trial presents biological evidence consistent with antiproliferative effects of metformin in women with EC in the clinical setting.

scholarly journals Decorin-Mediated Regulation of Fibrillin-1 in the Kidney Involves the Insulin-Like Growth Factor-I Receptor and Mammalian Target of Rapamycin

2007 ◽  
Vol 170 (1) ◽  
pp. 301-315 ◽  
Author(s):  
Liliana Schaefer ◽  
Wasiliki Tsalastra ◽  
Andrea Babelova ◽  
Martina Baliova ◽  
Jens Minnerup ◽  
...  
Keyword(s):  
Growth Factor ◽  
Mammalian Target Of Rapamycin ◽  
Target Of Rapamycin ◽  
Insulin Like Growth Factor ◽  
Factor I ◽  
Fibrillin 1 ◽  
Growth Factor I

MEDI-573, Alone or in Combination with Mammalian Target of Rapamycin Inhibitors, Targets the Insulin-like Growth Factor Pathway in Sarcomas

2014 ◽  
Vol 13 (11) ◽  
pp. 2662-2673 ◽  
Author(s):  
Haihong Zhong ◽  
Christine Fazenbaker ◽  
Shannon Breen ◽  
Cui Chen ◽  
Jiaqi Huang ◽  
...  
Keyword(s):  
Growth Factor ◽  
Mammalian Target Of Rapamycin ◽  
Target Of Rapamycin ◽  
Insulin Like Growth Factor
Sign in / Sign up

Export Citation Format

Share Document